Navigation Links
Sinovac Reports Unaudited First Quarter 2010 Financial Results
Date:5/13/2010

ry. Net income for the same period of 2009 included $126,000 of interest and financing expenses, $93,000 of interest and other income, and $482,000 of income tax expenses. Net loss attributable to shareholders for first quarter of 2010 was $307,000, or $0.01 loss per diluted share, as compared to net income attributable to shareholders of $25,000, or $0.00 per diluted share, in the same period of 2009.

As of March 31, 2010, Sinovac's cash and cash equivalents totaled $118.9 million, compared to $75.0 million as of December 31, 2009. The increase in cash and cash equivalents primarily reflects the contribution of approximately $62.0 million in net proceeds from the public offering of common shares, which closed in February 2010.

Recent Developments

Sinovac's 30%-owned joint venture, Sinovac Dalian, submitted an application to the SFDA to commence human clinical trials for its mumps vaccine. The proprietary mumps vaccine developed by Sinovac Dalian represents not only the first live attenuated vaccine for which Sinovac has filed a clinical trial application, but also the first candidate from the joint venture's pipeline for which a clinical trial application has been submitted to and accepted by the SFDA since the formation of the joint venture in January 2010.

After receiving regulatory approval from China's State Administration of Foreign Exchange, Sinovac Biotech, through it
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
2. Sinovac Announces Upsizing and Pricing of Common Share Offering
3. Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
4. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
5. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
6. Sinovac Reports Unaudited Third Quarter 2009 Financial Results
7. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
8. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
9. Sinovac to Present at 2009 UBS Global Life Sciences Conference
10. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
11. Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... -- Research and Markets ( ... "Biotechnology for the Non-Biotechnologist" conference to ... ideal for non-Scientists and Scientists needing to understand ... biotechnology. Ideal for Non-Scientists and Scientists ... and potential of biotechnology Why you ...
(Date:7/6/2015)... 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: ... Novella Clinical (Novella), to conduct the phase ... diagnosed glioblastoma. Novella is a full-service, global clinical research ... mid-sized oncology companies. The ICT-107 phase 3 trial will ... Europe and Canada ...
(Date:7/3/2015)... 3, 2015 ... osoitteessa  http://www.openinnovationinscience.at Wienissä pidettävään ... Science" -jatkokoulutusohjelmaan 22.7.2015 asti.  ... tekemän, kansainvälisiä tutkijoita ja tiedemiehiä ... suurinta haastetta ovat kannustimien puute ...
(Date:7/3/2015)... , July 3, 2015 ... 22 september 2015 på  http://www.openinnovationinscience.at till ... in Science" som hålls i ... färsk undersökning med internationella forskare och vetenskapsmän ... är hälsovetenskapens två största utmaningar bristen på ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3
... Report reveals robust investment in the industry; ... BOSTON, May 20 The global biotechnology industry,achieved ... 2007, as investors,and strategic partners showed strong confidence ... will continue to test the,industry in 2008. These ...
... Mass. -- May 19, 2008 -- Engineers ... demonstrated the first room-temperature electrically-pumped semiconductor source ... as T-rays. The breakthrough in laser technology, ... potential to become a standard Terahertz source ...
... Princeton University have created a new kind of ... mechanical properties, could be used in everything from ... nanocomposite that incorporates functionalized, exfoliated graphene sheets, even ... property to eventually create thermally stable, optically transparent ...
Cached Biology Technology:Record Venture Capital and Heated Deal Environment Propel Global Biotechnology Industry Forward in 2007 2Record Venture Capital and Heated Deal Environment Propel Global Biotechnology Industry Forward in 2007 3Record Venture Capital and Heated Deal Environment Propel Global Biotechnology Industry Forward in 2007 4Record Venture Capital and Heated Deal Environment Propel Global Biotechnology Industry Forward in 2007 5Engineers demonstrate first room-temperature semiconductor source of coherent Terahertz radiation 2By adding graphene, researchers create superior polymer 2
(Date:6/23/2015)... PALM BEACH GARDENS, Fla. , June ... of multi-factor identity management and authentication solutions, today ... Altus strong, multi-factor authentication solution.  The ... ease of use of the DigitalPersona Altus ... and biometric reader compatibility. In ...
(Date:6/18/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market announces that its Wocket® smart wallet ... on the Mark", scheduled to air on WABC Radio (am770) ... th . The broadcast air- time for ... 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira will ...
(Date:6/17/2015)... , and HILDEN, Germany , June ... QGEN ; Frankfurt Prime Standard: QIA) today launched new Investigator ... in forensic laboratories in the United States ... to simultaneously analyze multiple key genomic markers (short tandem repeats ... Quality Sensor to evaluate the quality of DNA in ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... Bethesda, MD FASEB MARC (Minority Access to ... for the 2011 American College of Sports Medicine (ACSM) ... 3-5, 2011. These awards are meant to promote the ... the mainstream of the basic science community and to ...
... the Deepwater Horizon rig in the Gulf of Mexico last ... and threatened Gulf ecosystems, the local Gulf Coast economy and ... at Rice University,s Baker Institute for Public Policy will examine ... scientific and technical information. The conference will feature academic scholars ...
... cell-based fluorescent assay they developed, scientists with the ... Laboratory (Berkeley Lab) and the University of California ... fluoxetine, the active ingredient in Prozac, suppresses the ... has been implicated in mood regulation and could ...
Cached Biology News:A second pathway for antidepressants 2A second pathway for antidepressants 3